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Introduction {#sec005}
============

Major depressive disorder (MDD) is a chronic mental illness that is characterized by persistent sadness and loss of interests for a minimum of two weeks \[[@pone.0172270.ref001]--[@pone.0172270.ref002]\]. Brain derived neurotrophic factor (BDNF) is a neurotrophic protein that has an important role in axonal growth, synaptic plasticity, and neuronal repair, and its levels are affected by stress \[[@pone.0172270.ref003]--[@pone.0172270.ref005]\]. There is growing evidence indicating that BDNF is related to many psychiatric disorders such as MDD in human studies \[[@pone.0172270.ref006]--[@pone.0172270.ref008]\].

Ever since Karege et al \[[@pone.0172270.ref009]\] demonstrated lower serum BDNF levels in depressed patients, considerable work has been carried out to investigate the relationship between decreased peripheral BDNF levels and pathogenesis of MDD \[[@pone.0172270.ref010]--[@pone.0172270.ref013]\]. Alternatively, several clinical studies pointed out that the down-regulation of peripheral BDNF levels in MDD patients could be reversed after a period of antidepressants (ADs) treatment. In parallel, earlier meta-analyses showed that peripheral BDNF levels were increased after pharmacological treatments \[[@pone.0172270.ref013], [@pone.0172270.ref014]\]. Moreover, several studies have investigated that ECT and different classes of antidepressants such as the serotonin selective reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs) have effects on the peripheral BDNF in MDD patients \[[@pone.0172270.ref015]--[@pone.0172270.ref018]\]. However, whether all the antidepressants have effects on the BDNF levels remains controversial. For instance, Matrisciano et al found that both sertraline (an SSRI) and venlafaxine (an SNRI) could increase BDNF levels, while escitalopram (an SSRI) did not affect BDNF levels at either time point \[[@pone.0172270.ref019]\]. Başterzi et al. found that fluoxetine (an SSRI) changed the BDNF levels of the patient group with treatment, but venlafaxin could not \[[@pone.0172270.ref020]\]. Molendijk et al. previously observed that the use of SSRIs was related to the increase in serum BDNF level \[[@pone.0172270.ref010]\]. These results suggested that differential antidepressants may have variable effects on peripheral BDNF levels during treatment, which is still not well known.

Accordingly, BDNF may have potential use as a predictor of antidepressant efficacy, and abundant clinical data from pre-antidepressant and antidepressant-treated depressed patients motivated us to investigate the differential effects of antidepressant drugs on BDNF concentrations. We therefore performed a systematic review and meta-analysis aiming to examine the action of various reported antidepressant drugs on peripheral BDNF levels in MDD patients.

Methods {#sec006}
=======

The study design was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement guidelines ([S1 Text](#pone.0172270.s001){ref-type="supplementary-material"}).

Search strategy {#sec007}
---------------

Electronic databases (PubMed, EMBASE, the Cochrane Library, Web of Science, and PsycINFO) were systematically searched ([S2 Text](#pone.0172270.s002){ref-type="supplementary-material"}, which summarizes the applied search strategies). All previous human studies through June 2016 (published original clinical studies, conference proceedings, meta-analyses) comparing pre- and post-antidepressant treatment peripheral BDNF levels were considered. The search terms were settled as: ("brain derived neurotrophic factor" OR BDNF), "antidepressant", AND ("major depression" OR "major depressive disorder" OR MDD OR "depressive episode" OR "depression").

Study selection strategy {#sec008}
------------------------

Three independent researchers (TL, JJZ, and XD) selected studies for inclusion with discrepancies resolved by discussion. The titles and abstracts were scanned, and potentially relevant studies were reviewed in full. We included eligible studies examining plasma or serum BDNF levels in patients pre- and post-antidepressant treatment. Furthermore, each included study should make descriptions of the antidepressant use and time points in the therapy. Since we focused on the effect of pharmacological treatments on BDNF levels, studies using antidepressant treatment such as electroconvulsive therapy (ECT) or deep brain stimulation (DBS) were not suitable for this meta-analysis. Abstracts, case studies, family-based designs, population-based studies on healthy subjects, reviews, and duplicate cohorts were excluded.

Data extraction and outcome measures {#sec009}
------------------------------------

Three authors (TL, CJZ, and BZ) independently extracted data to avoid extraction errors. The following parameters were extracted from each eligible article: first author, publication year, country of origin, diagnostic system, number of subjects (male/female), antidepressants use, measuring sample (plasma or serum), BDNF levels, and Hamilton Depression Rating Scale (HDRS) scores. The primary outcome was BDNF levels from baseline to post-treatment and we extracted the data for short-term (1 to 12 weeks) in each study. If one study reported BDNF concentrations for more than one time point within our pre-defined periods, we considered the data recorded at baseline and the last time point within the range for the overall effect analysis.

Statistical methods {#sec010}
-------------------

First, all statistical analyses for meta-analysis were conducted using Rev Man 5.0.1 and STATA software (version 12.1; Stata Corporation, College Station, Texas, USA). All *P*-values were two-sided with a *P*\<0.05 considered statistically significant. The alterations before and after antidepressant medication were assessed by SMDs (and their 95% CIs) for each study. A chi-squared-based Q-statistic test was used to detect the heterogeneity among studies, and a random-effects model was applied. We used a Z-test to determine the significance of the pooled SMDs with a *P*\<0.05 considered statistically significant. Stratification-based analyses were carried out to evaluate heterogeneity and the possible moderating effects of between-study differences on outcomes.

In order to evaluate possible biases, a sensitivity analysis was conducted by leave--one-out methods to assess the contribution of each individual dataset to the pooled OR. Finally, we estimated publication bias by Egger's test with a P\<0.05 considered statistically significant.

Result {#sec011}
======

The study selection procedure is shown in [Fig 1](#pone.0172270.g001){ref-type="fig"} **([Fig 1](#pone.0172270.g001){ref-type="fig"})**. The literature search identified 206 potentially relevant records. After screening titles and abstracts, 56 full-text articles were reviewed, of which 36 were excluded for the following reasons: (i) two studies were duplicated cohorts; (ii) five studies were reviews or meta-analyses; (iii) seven studies did not assess BDNF pre- and post- antidepressant treatment; (iv) six studies compared the BDNF val66met SNP; (v) twelve studies did not compare antidepressant medication but analyzed effects of other methods(ECT, sleep deprivation therapy, exercise et al) on BDNF; (vi) data from two studies could not be obtained; (vii) two studies did not measure BDNF, either in plasma or serum. Hence, twenty studies were ultimately included in this meta-analysis based on our inclusion criteria \[[@pone.0172270.ref019], [@pone.0172270.ref021]--[@pone.0172270.ref039]\]. The study characteristics are displayed in [Table 1](#pone.0172270.t001){ref-type="table"}. The characteristics of antidepressants such as antidepressants types, dose of antidepressants and duration of antidepressants treatment et al. are displayed in [Table 2](#pone.0172270.t002){ref-type="table"}.

![Flowchart of Study Selection.](pone.0172270.g001){#pone.0172270.g001}

10.1371/journal.pone.0172270.t001

###### Characteristics of 20 included studies (studies are sorted by year and month of publication).

![](pone.0172270.t001){#pone.0172270.t001g}

  Study         Year   Country       Diagnostic   Antidepressants                 Number(F/M)   Mean age      BDNF     HDRS                                          
  ------------- ------ ------------- ------------ ------------------------------- ------------- ------------- -------- --------------- -------------- -------------- ------------
  Mikoteit      2015   Switzerland   DSM-IV       SNRI                            25(8/17)      43.7±12.5     serum    5.01±3.64       7.3±5.6        22.2±4.9       9.0±6.6
  Ghosh         2015   India         DSM-IV       SSRI,SNRI                       60(32/28)     33.6±8.9      plasma   767.91±29.455   848.05±28.87   18.5±3.92      9.62±3.865
  Yoshimura     2014   Japan         DSM-IV       SSRI                            60            50.4±15.1     serum    8.6±7.2         11.2±8.4       21.0±4.3       10.0±5.6
  Brunoni       2014   Brazil        MINI         SSRI                            18            41.0±1.0      plasma   1331±786        1620±672       22.0±4.0       14.0±8.0
  Martocchia    2014   Switzerland   DSM-IV       SSRI                            5             74.0±6.8      serum    11.5 ± 0.6      16.0 ± 2.7     ---            ---
  Munno         2013   Italy         DSM-IV       SSRI                            16            48.19±10.3    serum    14.87±2.9       14.69±1.6      19.20±1.83     12.44±2.40
                                                                                                              plasma   231.4±90.1      312.9±109.4    19.20±1.83     12.44±2.40
  Ladea         2013   Romania       DSM-IV       SSRI                            20            36.6±8.1      serum    35.6±12.7       35.7±13.2      ---            ---
  Deuschle      2013   Germany       DSM-IV       SNRI, Mirtazapine               56(41/15)     52.3±15.9     serum    7.73±6.99       7.84±5.49      22.85±4.35     8.15±5.65
  Dreimüller    2012   Germany       DSM-IV       SSNRI, SNRI, TCA, Mirtazapine   39(19/20)     44.9±13.9     plasma   298±196         334±157        19             12
  Wolkowitz     2011   USA           DSM-IV       SSRI                            30(9/21)      39.1±9.6      serum    14.85±5.34      19.12±7.05     25.2±5.95      12.1±8.05
  Rojas         2011   Chile         DSM-IV       SNRI                            34(24/10)     41.05±11.15   serum    12.2±9.95       8.85±2.44      22.8±3.65      11.43±1.48
  Matrisciano   2009   Italy         DSM-IV       SSRI,SNRI                       21(10/11)     42.5±8.3      serum    35.37±14.33     39.43±14.97    17.6±5.3       ---
  Piccinni      2008   Italy         DSM-IV       SSNRI,SNRI,TCA                  15            47.0±10.8     serum    19.3±8.8        24.457±9.921   ---            ---
                                                                                                              plasma   290±190         456.3±198.5    ---            ---
  Huang         2008   China         DSM-IV       Mirtazapine. SSRI, SNRI         79(61/18)     37.3±10.0     serum    10.7±7.3        12.0±8.9       35.1±4.9       12.1±10.8
  Hellweg       2007   Germany       DSM-IV       TCA,SSRI                        20(17/3)      50.5±14.4     serum    13.13±4.43      13.60±5.41     23.4±4.5       11.35±8.25
  Yoshimura     2007   Japan         DSM-IV       SSRI,SNRI                       42(26/16)     46±20.5       serum    9.6±8.8         16.85±7.85     23.5±6.5       ---
  Aydemir       2006   Turkey        DSM-IV       SSRI                            20(20/0)      35.55±7.58    serum    27.68±13.74     38.57±15.30    39.75±7.40     9.31±6.05
  Gonul         2005   Turkey        DSM-IV       SSRI,SNRI                       28(21/7)      35.5±8.1      serum    20.8 ± 6.7      33.3±9.89      27.28 ± 3.53   8.85±3.15
  Aydemir       2005   Turkey        DSM-IV       SNRI                            10(8/2)       31.8±14.3     serum    17.9±9.1        34.6±7.1       23.2±4.6       8.2±3.9
  Shimizu       2003   Japan         DSM-IV       SSRI,SNRI                       4(2/2)        46.0±12.2     serum    13.32±11.97     28.79±6.23     33.5±10.5      2.8±1.0

BDNF concentration: Serum, ng/ml; Plasma, pg/ml. SSRI, Selective Serotonin Reuptake Inhibitor. SNRI, selective noradrenalin reuptake inhibitors. TCA, tricyclic antipsychotics.

10.1371/journal.pone.0172270.t002

###### BDNF levels of different point times and antidepressant treatment.

![](pone.0172270.t002){#pone.0172270.t002g}

  Study         Drug group                                                                                 Dose               Sample   Outcome   BL             1 week        2 week        4 week       6 week        8 week          12 week
  ------------- ------------------------------------------------------------------------------------------ ------------------ -------- --------- -------------- ------------- ------------- ------------ ------------- --------------- -------------
  Mikoteit      Duloxetine (SNRI)                                                                          65.8±16.1mg/day    Serum    BDNF      5.01±3.64      8.66±5.93     11.03±8.0                  7.3±5.6                       
                                                                                                                                       HDRS      22.2±4.9       16.8±7.5      13.8±7.5                   9.0±6.6                       
  Ghosh         Fluoxetine (SSRI)                                                                          20mg/day           Plasma   BDNF      775.32±30.38                                            N/A                           850.3±24.92
                                                                                                                                       HDRS      19±4.09                                                 12.2±4.58                     9.24±3.98
                Venlafaxine (SNRI)                                                                         50mg/day           Plasma   BDNF      760.5±28.53                                             N/A                           845.8±32.82
                                                                                                                                       HDRS      18±3.75                                                 13.5±3.86                     10±3.75
  Yoshimura     Paroxetin (SSRI)                                                                           30.5±12.4 mg/day   Serum    BDNF      8.6±7.2                                    9.2±6.1                    11.2±8.4        
                Sertraline (SSRI)                                                                          76.7±24.0mg/day             HDRS      21.0±4.3                                   13.8±4.9                   10.0±5.6        
                Fluvoxamin (SSRI)                                                                          100±26.3 mg/day                                                                                                             
  Martocchia    Escitalopram (SSRI)                                                                        10mg/day           Serum    BDNF      11.5±0.6                                                              16.0±2.7        
                                                                                                                                       GDS       9.6±3.4                                                               6.4±3.6         
  Brunoni       Sertraline (SSRI)                                                                          50mg/day           plasma   BDNF      1331±786                                                              1620±672        
                                                                                                                                       HDRS      22.0±4.0                                                              14.0±8.0        
  Munno         Paroxetin (SSRI)                                                                           20-50mg/day        Serum    BDNF      14.87±2.9                                                             14.69±1.6       
                                                                                                                                       HDRS      19.20±1.83                                                            12.44±2.40      
                                                                                                                              Plasma   BDNF      231.45±90.08                                                          312.95±109.42   
                                                                                                                                       HDRS      19.20±1.83                                                            12.44±2.40      
  Ladea         Escitalopram(SSRI)                                                                         10mg/day           Serum    BDNF      35.6±12.7                                  34.7±11.8                                  35.7±13.2
                                                                                                                                       MADRS     29.6±2.3                                                                              
  Deuschle      Venlafaxine (SNRI)                                                                         203±47mg/day       Serum    BDNF      7.82±3.75                                  7.18±5.64                                  
                                                                                                                                       HDRS      23.0±4.5                                   7.4±5.3                                    
                Mirtazapine                                                                                46±9mg/day                  BDNF      7.64±6.23                                  8.50±5.37                                  
                                                                                                                                       HDRS      22.7±4.2                                   8.9±6.0                                    
  Dreimüller    SSNRI, SNRI, TCA, Mirtazapine, Tranylcypromine                                             N/A                Plasma   BDNF      298±196        334±157                                                                
                                                                                                                                       HDRS      19             12                                                                     
  Wolkowitz     Escitalopram (SSRI)                                                                        10-20mg/day        Serum    BDNF      15.28 ± 3.55                                                          17.46 ± 3.96    
                                                                                                                                       HDRS      31.2 ± 7.9                                                            14.5 ± 11.2     
                Sertraline (SSRI)                                                                          50-200mg/day                BDNF      14.43 ± 7.12                                                          20.77 ± 10.15   
                                                                                                                                       HDRS      19.2 ± 4.0                                                            9.7 ± 4.9       
  Rojas         Venlafaxine (SNRI)                                                                         75mg/day           Serum    BDNF      12.2±9.95                                               8.85±2.44                     
                                                                                                                                       HDRS      22.8±3.65                                               11.43±1.48                    
  Matrisciano   Sertraline (SSRI)                                                                          96.4±50.8 mg/day   Serum    BDNF      29.4±12.6                                               50.6±14.2                     
                                                                                                                                       HDRS      19±5.3                                                  N/A                           
                Escitalopram (SSRI)                                                                        16.4±3.8 mg/day             BDNF      44.4±16.4                                               38.6±14.4                     
                                                                                                                                       HDRS      14.3±5.9                                                N/A                           
                Venlafaxine (SNRI)                                                                         150±61 mg/day               BDNF      32.3±14.0                                               29.1±16.3                     
                                                                                                                                       HDRS      19.4±4.5                                                N/A                           
  Piccinni      Citalopram, Sertraline, Paroxetine, Amitriptyline, Imipramine, Trimipramine, Desipramine   N/A                Serum    BDNF      19.3±8.8       22.09±8.37    24.46±9.92                                               
                                                                                                                                       HDRS      22.8±5.3                                                                              
                                                                                                                              Plasma   BDNF      290.0±190.0    444.8±20.95   456.3±19.85                                              
                                                                                                                                       HDRS      22.8±5.3                                                                              
  Huang         Mirtazapine. Fluoxetine, Paroxetine, Venlafaxine                                           N/A                Serum    BDNF      10.7±7.3                                   12.0±8.9                                   
                                                                                                                                       HDRS      35.1±4.9                                   12.1±10.8                                  
  Hellweg       Amitriptyline (TCA)                                                                        150mg/day          Serum    BDNF      13.001±3.744                               15.18±5.98                                 
                                                                                                                                       HDRS      23.8±5.1                                   11.0±8.1                                   
                Paroxetine (SSRI)                                                                          40mg/day                    BDNF      13.250±5.112                               12.02±4.85                                 
                                                                                                                                       HDRS      22.6±3.9                                   11.7±8.4                                   
  Yoshimura     Paroxetine (SSRI)                                                                          31±13mg/day        Serum    BDNF      9.4±7.9                                    10.4±8.2                   17.9±7.6        
                                                                                                                                       HDRS      24±7                                                                                  
                Milnacipran (SNRI)                                                                         83±31mg/day                 BDNF      9.8±9.7                                    10.3±7.5                   15.8±8.1        
                                                                                                                                       HDRS      23±6                                                                                  
  Aydemir       Escitalopram (SSRI)                                                                        10 mg/day          Serum    BDNF      27.68±13.74                                             38.57±15.30                   
                                                                                                                                       HDRS      39.75±7.40                                              9.31±6.05                     
  Gonul         Fluoxetine, Venlafaxine                                                                    N/A                Serum    BDNF      20.8±6.7                                                              33.3±9.89       
                                                                                                                                       HDRS      27.28±3.53                                                            8.85±3.15       
  Aydemir       Venlafaxine (SNRI)                                                                         75 mg/day          Serum    BDNF      17.9±9.1                                                                              34.6±7.1
                                                                                                                                       HDRS      23.2±4.6                                                                              8.2±3.9
  Shimizu       Amoxapine, Milnacipran, Paroxetine                                                         N/A                Serum    BDNF      13.32±11.97                                                           28.79±6.23      
                                                                                                                                       HDRS      33.5±10.5                                                             2.8±1.0         

BDNF concentration: Serum, ng/ml; Plasma, pg/ml. SSRI, Selective Serotonin Reuptake Inhibitor. SNRI, selective noradrenalin reuptake inhibitors. TCA, tricyclic antipsychotics.

Studies of antidepressants types {#sec012}
--------------------------------

The twenty studies were pooled together to assess the effect of antidepressant drugs on the BDNF levels before and after treatment. The random effects model was applied, and a pooled analysis of 20 studies showed a significant effect of antidepressants therapy on elevation of BDNF levels (SMD = 0.62, 95% CI = 0.31--0.94, Z = 3.92, *P*\<0.0001; **[Fig 2](#pone.0172270.g002){ref-type="fig"}**), as well as depressive symptoms amelioration with a significant decreased HDRS score (SMD = 2.78, 95% CI = 2.31--3.26, Z = 11.57, *P* \< 0.00001; **[Fig 3](#pone.0172270.g003){ref-type="fig"}**). I^2^ were respectively 85%and 83% suggesting strong heterogeneity.

![Meta-Analyses for the levels of BDNF pre- and post- antidepressant drugs treatment (less than 12 week).](pone.0172270.g002){#pone.0172270.g002}

![Meta-Analyses for the improvement of depressive symptoms after ADs (less than 12 week).](pone.0172270.g003){#pone.0172270.g003}

We next conducted an analysis from the studies based on the antidepressant drugs use. After stratification with SSRIs and SNRIs, the effect size as the changes in BDNF concentrations pre and post-treatment was 0.68 for SSRIs (95% CI = 0.27--1.10, Z = 3.22, *P* = 0.001; **[Fig 4A](#pone.0172270.g004){ref-type="fig"}**), and 0.92 for SNRIs (95% CI = 0.07--1.77, Z = 2.12, *P* = 0.03; **[Fig 4B](#pone.0172270.g004){ref-type="fig"})**. Then efficacy of differential drugs on the BDNF levels after treatment was analyzed. ADs that were only reported in single studies (fluoxetine, duloxetine, mirtazapine, amitriptyline, and milnacipran) or used in combination were excluded. Finally, four types of antidepressants (venlafaxine, paroxetine, sertraline and escltalopram) were analyzed for ease of analysis. According to the SMD and 95%CIs, sertraline showed a statistically significant effect on the BDNF levels pre- and post ADs treatment (SMD = 0.53,95% CI = 0.13--0.93, Z = 2.62, *P*  =  0.009), while no evidence for paroxetine, sertraline and escltalopram in BDNF changes was observed (**[Fig 5](#pone.0172270.g005){ref-type="fig"})**

![Antidepressants- Stratified Subgroup Meta-Analyses.\
Forest plots showing the summary effect sizes for levels of BDNF pre- and post- different kind of antidepressant drugs treatment (less than 12 week). (A) using SSRIs;(B) using SNRIs.](pone.0172270.g004){#pone.0172270.g004}

![Meta-Analyses for the levels of BDNF pre- and post- antidepressant with differenti drugs treatment (less than 12 week).\
Forest plots showing summary effect sizes of differential antidepressants (venlafaxine, paroxetine, sertraline and escitalopram) on BDNF concentration changes](pone.0172270.g005){#pone.0172270.g005}

Heterogeneity and moderation analyses {#sec013}
-------------------------------------

We performed the subgroup analysis based on the clinical samples used. Of all the included studies, seventeen described the alteration of BDNF levels in serum and five in plasma. The sample-stratified analysis indicated a significant higher level of BDNF concentration post-treatment with an effect-size estimate in serum (SMD = 0.46, 95% CI = 0.20--0.72, Z = 3.43, *P* = 0.0006), which was not observed in plasma (**[Fig 6](#pone.0172270.g006){ref-type="fig"}**). In the subgroup meta-analysis based on length of treatment, a statistically significant overall effect size was observed after 8 weeks of antidepressants treatment (SMD = 0.71, 95% CI = 0.37--1.05, Z = 4.14, *P* \< 0.0001) for the elevation of BDNF levels **([Fig 7](#pone.0172270.g007){ref-type="fig"})**.

![Sample- Stratified Subgroup Meta-Analyses.\
Forest plots showing the summary effect sizes for levels of BDNF pre- and post- antidepressant drugs treatment (less than 12 week) in serum (A) or plasma(B).](pone.0172270.g006){#pone.0172270.g006}

![Meta-Analyses for BDNF concentrations at different treatment time points during antidepressants treatment (less than 12 week).\
Forest plots showing the summary effect sizes for BDNF concentration changes at 4 weeks, 6 weeks, 8 weeks, and 12 weeks.](pone.0172270.g007){#pone.0172270.g007}

Sensitivity and publication bias {#sec014}
--------------------------------

Sensitivity analyses were conducted using the leave-one-out method by removing studies one by one to assess the degree to which each individual study influenced the results of the overall analysis. The results of the sensitivity analysis confirmed that no single study influenced the pooled SMDs. No strong statistical evidence for publication bias was observed in Egger׳s test (all *P*\>0.05).

Discussion {#sec015}
==========

In the present study, we summarized the existing literature and conducted a systematic analysis to evaluate the association between BDNF levels and antidepressant drug treatment. We included 20 studies that described comparisons of average BDNF levels pre- and post-antidepressant treatment with SSRIs, SNRIs, TCAs et al. First, we performed systematic meta-analyses and found that subjects with MDD had significantly higher BDNF concentrations after a short-term period (less than 12 weeks) of antidepressants treatment, accompanied by reduced HDRS scores. Consistent with previous works by Molendijk et al, lower serum BDNF in MDD could be normalized during antidepressant treatment \[[@pone.0172270.ref010]\]. Although we did not discuss whether BDNF concentration was correlated with depressive symptom alleviation, a significant negative relevance between depressive symptom alleviation and BDNF concentrations has been reported \[[@pone.0172270.ref013]\].

Molendijk et al. previously observed that the use of SSRIs was related to the increase in serum BDNF levels, which suggested that increases in serum levels of BDNF during antidepressant treatment appear to be confined to some antidepressants \[[@pone.0172270.ref010]\]. To uncover potential differences between various classes of antidepressants, we compared BDNF levels in MDD after SSRIs and SNRIs treatment. In our present study, we found that not only SSRIs but also SNRIs could increase BDNF levels over the course of antidepressant treatment. Making comparisons of four ADs by performing meta-analyses, only sertraline (but not venlafaxine, paroxetine or escitalopram) increased the BDNF levels. Fluoxetine was not analyzed because there was only one study that reported detailed data involving fluoxetine and BDNF.

Length of antidepressants treatment from 4 to 12 weeks was analyzed for contributions to the origin of the heterogeneity in our subgroup meta-analysis, and antidepressants had significant effect on the increase in BDNF concentration after 8 weeks of treatment. Notably, the temporal correlation between serum BDNF levels and the antidepressant effect is not direct: ketamine and ECT treatment increase serum BDNF levels only gradually while their antidepressant effect appears to be quick. While response to ADs treatment in depression was mostly chronic, with subjects in most studies still presenting with depressive symptoms at follow-up, the effect of antidepressant drugs on the BDNF levels may take a long time \[[@pone.0172270.ref040]\].

After stratifying the subgroup analyses based on clinical blood sampling, serum BDNF levels (as opposed to plasma levels) increased significantly after ADs treatment, while the plasma BDNF levels did not show significant differences; however, a high level of heterogeneity still existed. The significances of the lower BDNF levels in the peripheral blood from subjects with depression were recently reported worldwide in many clinical studies. However, the underlying mechanisms remained unclear. BDNF in the plasma or serum could be released from blood platelets \[[@pone.0172270.ref041], [@pone.0172270.ref042]\]; on the other hand, BDNF could be derived from the brain across the blood-brain-barrier (BBB)\[[@pone.0172270.ref043],[@pone.0172270.ref044]\]. Increases in serum BDNF levels with antidepressant treatment have been reported in multiple human and preclinical studies. Chronic administration of ADs could increase the expression of BDNF mRNA and protein in the prefrontal cortex, hippocampus, and other emotion-processing related regions \[[@pone.0172270.ref045]--[@pone.0172270.ref047]\]. In the overall meta-analysis, we found that the administration of ADs could alleviate the depressive symptoms, and increase the BDNF levels after a time period ranging from 2 to 12 weeks, indicating that changes in serum BDNF levels were significantly correlated with antidepressant treatment. Our subgroup-analysis results suggest that serum BDNF levels increased over the course of antidepressant treatment which was consistent with previous work, while plasma BDNF levels were not observed to be correlated with antidepressant treatment. Our results showed that the detection of BDNF in serum appears to be more reliable.

Mature brain-derived neurotrophic factor (BDNF) is initially synthesized and converted from its precursor protein proBDNF by tPA and extracellular proteases such as matrix metalloproteinase-9 (MMP-9)\[[@pone.0172270.ref048]--[@pone.0172270.ref050]\]. Both mature BDNF and proBDNF were proved to have important biological function in the pathology of psychiatric disorders such as MDD \[[@pone.0172270.ref051]--[@pone.0172270.ref053]\]. Mature BDNF and proBDNF in human blood could be distinguished with specific antibody by Western Blotting method. In fact, peripheral BDNF levels were mostly measured using an unspecific antibody BDNF ELISA kits for a larger sample size more conveniently and accurately. However, it was difficult to distinguish between proBDNF and mature BDNF in the ELISA kits due to the limited specificity of the BDNF antibody. A work by Yoshida et al. found that serum levels of mature BDNF, but not proBDNF were significantly lower in patients with MDD \[[@pone.0172270.ref054]\]. Serum mature BDNF levels in the MDD patients were significantly lower than those in the healthy controls, while no difference was found in serum proBDNF \[[@pone.0172270.ref055]\]. Therefore, it is likely that mature BDNF contributes to the decreased levels of BDNF in patients with MDD \[[@pone.0172270.ref017]\].

There exist some possible determinants that could influence serum BDNF. Serum BDNF concentrations systematically vary over the year, and decrease significantly over the autumn-winter period (Jan to May) while increasing in the spring-summer period \[[@pone.0172270.ref056]\]. Furthermore, other factors such as sampling, the number of sunlight hours, socio-demographics, lifestyle indicators, and disease can influence BDNF levels in humans \[[@pone.0172270.ref056]--[@pone.0172270.ref057]\]. In our meta-analyses, because of the limited information obtained from each included study, only the sample using and length of treatment duration were analyzed and shown to be potential factors that contribute to the pooled effects and the heterogeneity between studies. Nonetheless, serum levels of BDNF in humans may be influenced by seasonal variation, sex, sunshine hours, blood withdrawal, storage, smoking status, and food and alcohol intake \[[@pone.0172270.ref010], [@pone.0172270.ref056], [@pone.0172270.ref057]\].

There are several other limitations with respect to our findings. Firstly, we considered a treatment period within 12 weeks for BDNF analysis. Some ADs may take longer to affect BDNF levels once the depressive symptoms have improved. Secondly, BDNF is a hot topic in depression research worldwide. We only included the English studies in our meta-analysis, which may be a source of publication bias although no such publication bias was found in our meta-analysis. Thirdly, some ADs such as fluoxetine, duloxetine, mirtazapine, amitriptyline, and milnacipran were only reported in single study, so it was difficult to estimate their true effects on the increase of BDNF levels in our analyses. It is important to point out here that these drugs were reported to increase BDNF levels in their respective studies. In some clinical studies, drugs were used in combination which may explain the observed heterogeneity. In addition, drug dose of antidepressant should be analyzed as a modifier for changes of BDNF levels. Due to the limited information and a wide variation in dose, it is difficult to define and divide the dose, so the analysis was not able to be carried out.

In summary, our meta-analyses of 20 studies related to depression provided evidence that peripheral BDNF levels are increased during the course of antidepressant drug treatment (SSRIs and SNRIs). Our study also provided further evidence of the possible mechanisms and effects of different ADs on BDNF levels. Peripheral BDNF levels are better documented in serum than in plasma which would be useful in future research studies of BDNF and antidepressant treatment. Sertraline was shown to increase BDNF levels after a short-term period of treatment, and may be a good candidate for the exploration of ADs pharmacological mechanisms related to peripheral BDNF.
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